ThermoGenesis Holdings, Inc. · OTC:THMO

ThermoGenesis — Corporate Update (May 2020)

18 slides from ThermoGenesis's corporate update, May 14, 2020

  1. Slide 1: A Corporate Update in the Fight against COVID-19

    Exhibit 99.2 ——-A leader in cellular processing ‘A solution provider for automated cell processing tools and services in the cell & gene therapy field” A Corporate Update in the Fight against COVID-19 May 14, 2020 ; x © 2020 ThermoGenesis Holdings, Inc. (NASDAQ:THMO) ThermoGenesis

  2. Slide 2: Disclosure and Forward-Looking Statement

    2] Disclosure and Forward-Looking Statement This presentation includes statements of future expectations and other forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current

  3. Slide 3: About ThermoGenesis (est. 1986)

    3 J About ThermoGenesis (est. 1986) + Automated Cell Processing Tools and Medical Device Manufacturer: + CAR-TXpress™ Platform with X-BACS™ technology: Large scale immune cell manufacturing platform. Potentially reducing CAR-T cell manufacturing cost by 2/3 + AXP® and BioArchive® Systems: Best techn

  4. Slide 4: Significant Unmet Needs for COVID-19

    EG | signiicant Unmet Needs for COVID-19 How seasonal flu and Covid-19 compare Cane 6.1% Without an effective therapy, 20% of Flu COMO \ patients will be severe and critical Ro number 7 stage, and ~ 50% of critical “alveiiectesbyancege t q t ] { stage patients will die naval dace ors 13 228 Incubati

  5. Slide 5: Our Response: A Rapid 2-10min Antibody Test

    5 | Our Response: A Rapid 2-10min Antibody Test Rapid Covid-19 Serological IgG/lgM Test Collect Using the included lancet, 11 drop of fingertip blood is collected Load Blood and solution added to the included test cartridge (o) 6+ Le Il tne =— ‘© 2020 ThermoGenesis Holdings, Inc. (NASDAQ:THMO) Uncov

  6. Slide 6: Regulatory Filing Status Update

    | Regulatory Filing Status Update + OnMarch 31, 2020, the Company submitted filing in accordance with the “Policy for Diagnostic Test for Coronavirus Disease—2019 during the Public Health Emergency: Immediately in Effect Guidance for Clinical Laboratories, Commercial Manufacturer, and Food and Drug

  7. Slide 7: Antibody Test - Application Scenario and Needs

    ey Antibody Test - Application Scenario and Needs (1) Antibody test seen as key to re- opening country - used for screening individuals and work force with protective immunity — estimatedneeds ~330 million tests in the U.S. ‘© 2020 ThermoGenesis Holdings, Inc. (NASDAQ:THMO) Opinion Sport Culture Lif

  8. Slide 8: ThermoGenesis' Multi-tiered Antibody Therapy

    | ThermoGenesis’ Multi-tiered Antibody Therapy Patients develop Covid-19 antibody in convalescent plasma tse lhe ogo —s'e— go | ivga j— —| Evidences for Convalescent Plasma’s Clinical Efficacy Soha srl ye * Convalescent plasma improves the survival rate of patients with SARS i coronavirus shorter ho

  9. Slide 9: ThermoGenesis — A Leader in Cellular Processing

    ThermoGenesis — A Leader in Cellular Processing —A full product line of FDA registered medical devices for cell banking, cell process and celltherapy 1. AXP®/BioArchive® 2. PXP® Platform for 3. CAR-TXpress™ Platform Platform for Stem Cell Point-of-Care Clinical for Large Scale Cell Banking Manufactu

  10. Slide 10: AXP/BioArchive: Leading Technology for Cord Blood Banks

    atel | AXP/BioArchive: Leading Technology for Cord Blood Banks Fully automated system for the isolation of stem cells from cord blood with superior performance BioArchive® NYBC National Cord Blood Program AXP Processing Results: N=34,011 CBUs Recovery Volume [60 34+ viability | twostrcessin)_|Postpr

  11. Slide 11: Reducing CAR-T Manufacturing Cost Through Automation

    Reducing CAR-T Manufacturing Cost Through Automation —Introducing proprietary CAR-TXpress™ platform, potentially reduce manufacturing cost by 2/3 wrdeBkos ma Lear UN 9 ory3, Volumes May Exceed SL DNA Gene Insertion Additional IL-2 Infused a Modi ~ Bes 10-14 days X-WASH® Washing and Volume Reduction

  12. Slide 12: Cell Processing Product Pipeline

    22] Cell Processing Product Pipeline CAR-TXpress™ Platform — Potentially Reducing CAR-T Cell Mfg. Cost by 2/3 * In Q3 2019, TG entered into global distribution agreement for X-Series® products with Corning * Received $2M upfront license fee and access to global sales network AXP®/BioArchive® Platfor

  13. Slide 13: Financial Performance (Year-to-Year)

    13] Financial Performance (Year-to-Year) $15.0 $10.0 $5.0 $0.0 Revenue ($ in millions) $13.0 $07 l m8 9 Gross Profit ($ in millions) $6.0 $4.0 $2.0 $0.0 $5.7 $2.2 Baa 29 $15.0 $10.0 $5.0 $0.0 OpEx ($ in millions) $12.7 ] $10.4 209 208 $4.0 $3.0 $2.0 $1.0 $0.0 Cash ($ in millions) $: $2.4 i 3.2 2018

  14. Slide 14: Financial Performance (Quarter-to-Quarter)

    1a] Financial Performance (Quarter-to-Quarter) $3.3 $3.2 $3.4 $3.0 $2.9 Revenue ($ in millions) $3.2 Gross Profit ($ in millions) $1.6 SLS SLs Sia $1.3 $1.3 $1.2 = $2.8 $2.6 $2.4 $2.2 $2.0 OpEx ($ in millions) $2.7 $2.2 rowat 202001 Cash ($ in millions) $8.0 $6.0 $5.7 $4.0 $2.0 $0.0 “OpErup due to n

  15. Slide 15: Investment Values and Peer Group Comparison

    15 Investment Values and Peer Group Comparison — With stronger cash position heading into 2020, ThermoGenesis is at inflection point Scientific Tool and Service Companies in Cell & Gene Therapy Field Company ThermoGenesis Cryoport Ticker (Nasdaq:THMO) (Nasda x) ) Business ‘Automated Cell Process Too

  16. Slide 16: Board of Directors

    6 | Board of Directors Dr. Chris Xu, PhD, MBA | Chairman and Chief Executive Officer 20+ years in life sciences and pharmaceutical industry. Entrepreneur & investor, has invested in more than 20+ private and public companies. The largest investor of the Company. Dr. Russell Medford, MD, PhD | Indepe

  17. Slide 17: Executive Management Team

    ay, | Executive Management Team 6 an «Wy © 2020 ThermoGenesis Holdings, Inc. (NASDAQ:THMO) ThermoGenesis Chris Xu, PhD, MBA, Chairman and Chief Executive Officer 20+ years in life sciences and pharmaceutical industry. Entrepreneur & investor, has invested in more than 20+ private and public companie

  18. Slide 18: Pursuing Excellence In Cell Processing Technologies

    Pursuing Excellence In Cell Processing Technologies In the fight against COVID-19 Company Contact: ThermoGenesis Holdings, Inc. Wendy Samford 916-858-5191 ir@ThermoGenesis.com ‘© 2020 ThermoGenesis Holdings, Inc. (NASDAQ:THMO) Investor Contact: Rx Communications Paula Schwartz 917-322-2216 pschwartz

ThermoGenesis Holdings — Corporate Update (May 2020) on 6ix